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Summary 
Selective- and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) as well 
as acetaminophen belong to the most widely prescribed therapeutic agents 
worldwide. Their efficacy in pain relief notwithstanding, the use of NSAIDs is 
associated with an increased cardiovascular risk, which can be partly attributed to 
their blood pressure rising potential. Adequately powered placebo-controlled trials 
specifically evaluating cardiovascular safety of NSAIDs vs. selective COX inhibitors 
are currently underway. This review summarizes the current knowledge on 
cardiovascular effects of NSAIDs and acetaminophen and its potential clinical 
consequences. 
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Introduction 
Non-selective nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most 
used drugs worldwide. The therapeutic efficacy of these painkillers, however, 
comes at the cost of certain side effects, gastrointestinal and cardiovascular, in 
particular. 
Because the prolonged use of NSAIDs, and selective cyclooxygenase-2 (COX-2)-
inhibitors was shown to be associated with a rise in blood pressure and an 
increased risk of coronary artery disease and myocardial infarction,[1-3] current 
guidelines recommend avoiding NSAIDs and COX2-inhibitors in patients with high 
cardiovascular risk or established coronary artery disease (CAD), if feasible.[4]  
Arterial hypertension is a major risk factor for stroke, ischemic heart disease and 
heart failure,[5] and non-pharmacological and pharmacological antihypertensive 
therapies[6] [7] have been well documented to reduce morbidity and mortality in 
hypertension. Since NSAIDs and selective COX inhibitors may worsen blood 
pressure control,[8, 9] there is ongoing concern of their use in patients with arterial 
hypertension, particularly in resistant hypertension, where the concurrent use of 
painkillers including selective and nonselective NSAIDs, as well as acetaminophen 
should be excluded. This review aims to summarize the current knowledge about 
the effect of these drugs on blood pressure and cardiovascular outcome. 
 
NSAIDs  
Nonselective NSAIDs and COX-2 selective inhibitors increase blood pressure, in 
both normotensive subjects as well as in patients with hypertension, an effect 
independent of the presence of antihypertensive treatment.  
Two large metaanalysis[8, 9] evaluated the effect of nonselective NSAIDs in 
persons with normal blood pressure, demonstrating a small increase in mean 
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arterial pressure with regular use of NSAIDs. The mechanism for the increase in BP 
is most likely due to their impact on vasoactive endothelium-derived factors, 
particularly via the inhibition of prostaglandin synthesis, important for the regulation 
of vascular tone and sodium excretion. Other possible mechanisms underlying the 
hypertensive effects of NSAIDs are summarized in Table 1 
 
The blood pressure raising effect likely translates to higher cardiovascular risk, but 
this varies according to different types of NSAIDs as demonstrated in several meta-
analyses of observational studies[10, 11] demonstrating an higher cardiovascular 
risk associated with the use of diclofenac, indomethacin and ibuprofen as compared 
to naproxen.[12, 13] Interestingly, a large cohort study evaluated safety of NSAIDs 
in 50,000 patients recently hospitalized because of serious coronary heart disease, 
suggested a superior cardiovascular safety of naproxen compared with diclofenac, 
ibuprofen, rofecoxib, and celecoxib.[14]  
 
Selective COX2-Ihnibitors  
Selective COX-2 inhibitors (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, 
valdecoxib and lumiracoxib) were developed to reduce the risk of gastrointestinal 
side effects (such as symptomatic gastrointestinal ulcers and complications such as 
bleeding, perforation or gastric outlet obstruction) and to avoid the antiplatelet effect 
of traditional NSAIDs.   
Unfortunately, the gastrointestinal safety benefit of selective COX-2 inhibitors may 
come at the cost of an increased cardiovascular risk. The first concerns regarding 
the cardiovascular safety of COX2-inhibitors were related to the VIGOR study.[15] 
This study, planned to evaluate the upper gastrointestinal side effects of rofecoxib 
and naproxen in patients with rheumatoid arthritis, showed a significantly higher 
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incidence of cardiovascular thrombotic events in the group of patients receiving 
rofecoxib.[16] Remarkably, patients receiving rofecoxib 50 mg showed a five-fold 
increased risk of myocardial infarction (MI) as compared to the patients receiving 
naproxen 1000 mg. These observations were confirmed in the APPROVE study[17] 
designed to evaluate the incidence of adenomatous polyps in patients treated with 
rofecoxib 25 mg compared to placebo. The results of this study demonstrated a 
two-fold increase in myocardial infarction risk in patients treated with rofecoxib 
versus placebo and resulted in the removal of the drug from the market. Similarly, in 
the Adenoma Prevention with Celecoxib trial[18] an increased cardiovascular risk 
was found in the patients receiving celecoxib when compared to placebo. It is of 
note that these trials in colon polyp patients did not include traditional NSAIDs 
leaving the question unanswered whether these unselective COX-inhibitors would 
have increased cardiovascular risk as well.  
In contrast to APPROVE[17], APC[18] and PreSAP[19] in colon polyp patients, the 
analysis of the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT)[20] 
offered the opportunity to assess the effect of a COX-2 inhibitor (celecoxib) versus a 
traditional NSAID (naproxen) and placebo. While the results of the ADAPT trial was 
stopped prematurely because of concerns in the aftermath of the publication of the 
APC trial, ADAPT provides first prospective outcome trial evidence comparing a 
conventional NSAIDs versus a COX-2 selective agent. Importantly, naproxen did 
not appear to be safer than celecoxib, but rather showed a worrisome trend towards 
increased incidence of cardiovascular events.[20]  
In the MEDAL trial[21] in more than 30,000 patients with osteoarthritis and 
rheumatoid arthritis comparing the COX-2 inhibitor etoricoxib to diclofenac, the rate 
of thrombotic cardiovascular events with etoricoxib was similar to those in patients 
on diclofenac (even a small trend towards less fatal MI in the etoricoxib group: 6 vs 
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17; with no difference seen in the incidence of non-fatal MI).  
While two head-to-head clinical trials of coxibs versus traditional NSAIDs 
(PRECISION and SCOT) are currently underway[22, 23] observational studies 
showed the risk of myocardial infarction associated with the use of rofecoxib (OR 
1.32) to be similar to the one of non selective NSAIDs as diclofenac (1.55) and 
ibuprofen (1.24), once again emphasizing that conventional NSAIDs might be 
deleterious in this respect as well.[14] 
It was suggested that this excess of cerebrovascular events seen with COX-2 
inhibitors, especially rofecoxib, could be related to the effects on blood pressure.[16, 
24, 25] However, in the MEDAL study[21, 26] the use of etoricoxib was associated 
with a substantially greater blood pressure increase than diclofenac, but this 
increase in blood pressure was not related to the increased cardiovascular events in 
patients with osteoarthritis and rheumatoid arthritis treated with etoricoxib and 
diclofenac, indicating that other mechanisms than blood pressure alone contribute 
to the cardiovascular side effects of coxibs and NSAIDs. The so-called “COX-2 
hypothesis”, had suggested an increased cardiovascular toxicity of COX-2 inhibitors 
because of their higher COX-2 selectivity, which results in greater 
prostacyclin/thromboxane imbalance. Vascular health, however, is not determined 
by prostanoids alone, but by a variety of other endothelial factors, such as nitric 
oxide. Interestingly, differences with regard to endothelial function have been 
proposed to account for potential differences of different COX inhibitors. While 
rofecoxib does not improve endothelial function[27, 28], celecoxib improves nitric 
oxide bioavailability and endothelium-dependent vasodilatation and reduces 
vascular inflammation and oxidative stress in patients with ischemic heart disease, 
hypertension and rheumatoid arthritis.[29-31] 
In a prospective study by Sowers and coworkers[27] the effect of rofecoxib, 
 7 
celecoxib and naproxen on ambulatory blood pressure in 400 patients with arterial 
hypertension, diabetes mellitus and osteoarthritis was evaluated. Patients received 
stable antihypertensive and antidiabetic drugs during the whole study. Rofecoxib, 
but not celecoxib and naproxen, significantly increased 24-hour systolic blood 
pressure after 6 weeks of therapy. Other COX-2 inhibitors, like etoricoxib, did also 
elevate blood pressure,[25] while in the TARGET study ibuprofen (800 mg tid) and 
naproxen (500 mg bid) were associated with significantly greater changes in systolic 
blood pressure as compared to lumiracoxib (400 mg once daily).[32]  
Available information suggests that very few of any drug classes truly act as a 
class for structure, pharmacology, mode of action, efficacy and safety. Each 
individual agent should be therefore evaluated on its merits. Prospective randomized 
trials with adequate powered and independently run are needed to clarify the 
association between pain relief drugs and cardiovascular outcomes. The 
PRECISION – Prospective Randomised Evaluation of Celecoxib Integrated Safety vs. 
Ibuprofen and Naproxen - trial in more than 20,000 patients with osteoarthritis is 
currently under way. Until this trial and the ongoing SCOT trial by MacDonald and 
colleagues are completed, careful risk benefit analysis needs to be undertaken for all 
these agents with regard to their potential gastrointestinal benefit versus 
cardiovascular risk. 
Until now, all anti-inflammatory drugs, non-selective NSAIDs as well as 
selective COX-2 inhibitors should be individually evaluated regarding their risk 
benefit profile.  
 
Aspirin  
Aspirin may be considered a special nonselective NSAID, especially as it inhibits 
prostaglandin synthesis, and thus may therefore affect blood pressure as well.  
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Two meta-analyses evaluate the effect of aspirin on blood pressure in patients with 
arterial hypertension. Pope et al[9] included four trials studying the effect of aspirin 
in 39 hypertensive patients who took at least 1.5 g of aspirin daily (a dose notably 
much higher than suggested for prevention of CV disease). The authors showed 
that the use of aspirin was associated with an increase in mean blood pressure 
(+0.61±1.82 mmHg), an effect, however, not seen anymore after statistical 
adjustment for salt intake (mean blood pressure -1.76±2.04 mmHg). 
These results were similar to those of another meta-analysis[8] of 8 trials evaluating  
the effect of aspirin on supine blood pressure in 105 patients, where the 
administration of aspirin (1.5-2 gr/day) did not change blood pressure significantly. 
Of note, aspirin at higher doses may reduce the antihypertensive efficacy of 
angiotensin-converting enzyme (ACE) inhibition by interfering with prostaglandin 
synthesis. Therefore patients taking higher doses of aspirin may not profit as much 
from ACE inhibition as other patients.[33] 
In the Hypertension Optimal Treatment (HOT) Study[34-36] 18,790 patients with 
hypertension (mean age 61.5±7.5 years; blood pressure 169±14/105±3.4 mmHg) 
were randomized to receive either aspirin 75 mg or placebo daily in addition to their 
antihypertensive treatment for a follow-up period of 3.8 years. In this study[36] there 
were no differences in mean blood pressure achieved between patients randomized 
to low-dose aspirin or placebo (from 6 months to end of treatment, SBP 141.9±11.7 
and 141.3±11.6 mmHg; DBP 83.3±5.3 and 83.0±5.3 mmHg, respectively). 
Moreover, low-dose ASA did not interfere with the BP-lowering effect of 
antihypertensive agents, including combinations with ACE inhibitors. 
In conclusion the available data suggest that low-dose aspirin, as recommended for 
middle or high risk patients for prevention of cardiovascular events does not affect 
blood pressure in patients with arterial hypertension. These conclusions may not 
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hold true for larger doses of aspirin used for pain relief, or for patients with 
congestive heart failure.[35] 
 
Acetaminophen and blood pressure 
Because of concerns for negative cardiovascular effects of selective and non-
selective NSAIDs, acetaminophen has been suggested as a safer alternative for 
pain reducing and anti-inflammatory therapy in patients with osteoarthritis and 
comorbid cardiovascular disorders.[4] 
Prospective controlled studies with acetaminophen, however, are scarce, and the 
results inconsistent.[37] While one study showed a 4-mm Hg increase, two further 
studies showed no change in blood pressure associated with the use of 
acetaminophen in patients with hypertension.[38-40] It is of note that these studies 
were performed in patients with hypertension, not in the high-risk group of patients 
with established coronary heart disease in whom the use of acetaminophen is 
recommended by current guidelines.[4] 
In 2005 the risk of incident hypertension for women using aspirin, other NSAIDs, 
and acetaminophen was evaluated in the population included in the Nurses' Health 
Study I and II.[41] The multivariable adjusted relative risk of incident hypertension 
for women who took acetaminophen >500 mg per day was increased almost twofold 
compared with women who did not use acetaminophen.  
Two years later, the association between analgesic use and risk of incident 
hypertension was analyzed in the Health Professionals Follow-up Stud’s 
population[42]. Information about the use of acetaminophen, NSAIDs, and aspirin 
were collected at baseline and after 2 years follow-up in 16,031 male health 
professionals without a history of hypertension at baseline. This study showed that 
men who used acetaminophen 6 to 7 days per week compared with nonusers had 
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an increased relative risk for incident hypertension compared to non-steroidal anti-
inflammatory drugs.[42]  
In line with these epidemiological data, the results of our recently published 
prospective placebo-controlled study question the presumed acetaminophen's 
cardiovascular safety. This study was planned to evaluate the effect of 
acetaminophen (1g tid for 2 weeks) as compared to placebo on 24-hours blood 
pressure and endothelial function. In this study we provide evidence that 
acetaminophen increases ambulatory blood pressure in patients with stable 
coronary artery disease under stable cardiovascular therapy (Figure 1).[37] 
Importantly, the observed increase in blood pressure associated with the use of 
acetaminophen was within the range of the hypertensive effects of traditional 
NSAIDs, particularly diclofenac and ibuprofen.[43] 
As the use of acetaminophen is so prevalent, a hypertensive effect of this drug 
could be of public health concern. Indeed, in view of the established continuous 
incremental risk of cardio- and cerebrovascular disease in relation to blood pressure, 
an increase in blood pressure associated with the use of acetaminophen as 
observed could further substantially increase the risk of myocardial infarction and 
stroke, in patients at high cardiovascular risk or established cardio- or 
cerebrovascular disease in particular.[37, 43]  
Concerning the underlying mechanisms, acetaminophen however, is generally 
considered to be a relatively weak inhibitor of the prostaglandin synthesis[44, 45] 
compared to traditional NSAIDs. Moreover, the hypertensive effect of 
acetaminophen could be mediated by such central COX-3 activity or COX-2 
inhibition by acetaminophen[46] or by an indirect activation of cannabinoid CB(1) 
receptors.[47] 
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Intriguingly, in our study[37] the blood pressure increase induced by acetaminophen 
was paralleled by an increase, rather than the expected decrease in heart rate 
indicating a potential central effect of acetaminophen.  
 
Conclusions 
The use of selective and unselective NSAIDs as well as acetaminophen, particularly 
at high doses, is associated with an increase in blood pressure and an excess of 
cardiovascular risk.  
Because of the excess cardiovascular risk associated with pain-relieving drugs, 
many patients are now being withheld effective pain treatment. This is unethical and 
from a cardiovascular point of view counterproductive, as pain is increasingly 
considered as an important cardiovascular risk factor. Indeed, untreated pain 
increases heart rate, blood pressure and neurohumoral activation that combined 
with the forced immobilization further aggravates cardiovascular risk, thus 
potentially outweighing any putative risk of pain-relieving drugs. As such, patients in 
need of treatment for pain must not be withheld effective (pharmacological or non-
pharmocological) pain relieving therapy, but a close follow-up with regard to 
potential cardiovascular and gastrointestinal side effects is recommended.  
Hence, until evidence from the PRECISION and SCOT trial become available, 
careful risk benefit analysis needs to be undertaken for all pain-relieving agents with 
regard to their potential gastrointestinal benefit versus their potential cardiovascular 
risk hazard.  
Conventional NSAIDs, including acetaminophen and high-dose aspirin, should be 
scrutinized as rigorously as COX2 selective inhibitors. 
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Table 1 Potential mechanism underlying the blood pressure raising effects of 
non-steroidal anti-inflammatory drugs 
Inhibition of PGE2 and PGI2 production via the COX enzymes 
Greater vasoconstrictive effects from endothelin and increased release of 
norepinephrine due to reduced PGs production 
Decreased natriuresis 
Increased production of vasoconstrictive arachidonic acid derived substances 
Inhibition of aldosterone glucuronidation  
PG: prostaglandin, COX: cyclossigenase, 
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Figure 1 
 
 
Difference in mean 24-hour ambulatory blood pressure (Delta BP, mmHg) between 
baseline and treatment with acetaminophen and placebo. *: p<0.05 acetaminophen versus 
placebo. From Sudano I et al.[37] 
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